Which has higher earnings & valuation, FTRE or EVO?

Evotec has lower revenue, but higher earnings than Fortrea. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.68B 0.71 -$986.20M -$0.91 N/A Evotec $891.97M 0.64 -$117.12M N/A N/A

Is FTRE or EVO more profitable?

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Evotec -26.20% -24.93% -11.35%

Does the media prefer FTRE or EVO?

In the previous week, Fortrea had 3 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Fortrea and 5 mentions for Evotec. Fortrea's average media sentiment score of 0.50 beat Evotec's score of 0.04 indicating that Fortrea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MRVI or EVO?

Evotec has higher revenue and earnings than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maravai LifeSciences $185.74M 11.04 -$130.77M -$0.52 N/A Evotec $891.97M 0.64 -$117.12M N/A N/A

Does the media prefer MRVI or EVO?

In the previous week, Evotec had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Evotec and 2 mentions for Maravai LifeSciences. Evotec's average media sentiment score of 0.04 beat Maravai LifeSciences' score of 0.00 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, EVO or BLFS?

BioLife Solutions has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.64 -$117.12M N/A N/A BioLife Solutions $96.21M 18.97 -$4.59M $1.16 32.16

Is EVO or BLFS more profitable?

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% BioLife Solutions 53.29% 2.70% 2.49%

Does the media refer more to EVO or BLFS?

In the previous week, Evotec had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for Evotec and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.76 beat Evotec's score of 0.04 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLife Solutions 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, EVO or PSNL?

Personalis has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.64 -$117.12M N/A N/A Personalis $69.67M 24.47 -$81.27M -$1.09 N/A

Is EVO or PSNL more profitable?

Evotec has a net margin of -26.20% compared to Personalis' net margin of -153.84%. Evotec's return on equity of -24.93% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Personalis -153.84% -46.47% -35.30%

Does the media refer more to EVO or PSNL?

In the previous week, Evotec had 1 more articles in the media than Personalis. MarketBeat recorded 5 mentions for Evotec and 4 mentions for Personalis. Personalis' average media sentiment score of 0.06 beat Evotec's score of 0.04 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, EVO or AZTA?

Azenta has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.64 -$117.12M N/A N/A Azenta $593.82M 2.86 -$55.76M -$2.76 N/A

Is EVO or AZTA more profitable?

Azenta has a net margin of -20.63% compared to Evotec's net margin of -26.20%. Azenta's return on equity of 1.18% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Azenta -20.63% 1.18% 0.97%

Does the media refer more to EVO or AZTA?

In the previous week, Evotec and Evotec both had 5 articles in the media. Azenta's average media sentiment score of 0.36 beat Evotec's score of 0.04 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Azenta 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evotec (EVO) Competitors

$1.60 -0.05 (-2.74%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.60 +0.00 (+0.31%)

As of 10/2/2026 04:29 PM Eastern

Compare

EVO vs. FTRE, MRVI, BLFS, PSNL, and AZTA

Should you buy Evotec stock or one of its competitors? Evotec's main competitors and comparable companies include Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), Personalis (PSNL), and Azenta (AZTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Evotec compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Fortrea had 3 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Fortrea and 5 mentions for Evotec. Fortrea's average media sentiment score of 0.50 beat Evotec's score of 0.04 indicating that Fortrea is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.8% of Evotec shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evotec has lower revenue, but higher earnings than Fortrea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A

Fortrea presently has a consensus price target of $22.00, suggesting a potential upside of 10.00%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 87.50%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fortrea has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Evotec has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

Summary

Fortrea beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Evotec compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Evotec has higher revenue and earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	11.04	-$130.77M	-$0.52	N/A
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Evotec has a net margin of -26.20% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Evotec had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Evotec and 2 mentions for Maravai LifeSciences. Evotec's average media sentiment score of 0.04 beat Maravai LifeSciences' score of 0.00 indicating that Evotec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Evotec has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

Maravai LifeSciences presently has a consensus target price of $6.83, suggesting a potential downside of 13.50%. Evotec has a consensus target price of $3.00, suggesting a potential upside of 87.50%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Maravai LifeSciences and Evotec tied by winning 7 of the 14 factors compared between the two stocks.

How does Evotec compare to BioLife Solutions?

Evotec (NASDAQ:EVO) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

5.8% of Evotec shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioLife Solutions has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A
BioLife Solutions	$96.21M	18.97	-$4.59M	$1.16	32.16

Evotec currently has a consensus target price of $3.00, indicating a potential upside of 87.50%. BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 15.88%. Given Evotec's higher possible upside, research analysts plainly believe Evotec is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
BioLife Solutions	53.29%	2.70%	2.49%

Evotec has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

In the previous week, Evotec had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for Evotec and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.76 beat Evotec's score of 0.04 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLife Solutions beats Evotec on 9 of the 13 factors compared between the two stocks.

How does Evotec compare to Personalis?

Evotec (NASDAQ:EVO) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Evotec presently has a consensus price target of $3.00, indicating a potential upside of 87.50%. Personalis has a consensus price target of $14.54, indicating a potential downside of 10.71%. Given Evotec's higher probable upside, equities research analysts plainly believe Evotec is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Personalis has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A
Personalis	$69.67M	24.47	-$81.27M	-$1.09	N/A

5.8% of Evotec shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evotec has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Personalis has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

Evotec has a net margin of -26.20% compared to Personalis' net margin of -153.84%. Evotec's return on equity of -24.93% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Evotec had 1 more articles in the media than Personalis. MarketBeat recorded 5 mentions for Evotec and 4 mentions for Personalis. Personalis' average media sentiment score of 0.06 beat Evotec's score of 0.04 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Personalis beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Evotec compare to Azenta?

Evotec (NASDAQ:EVO) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Azenta has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.64	-$117.12M	N/A	N/A
Azenta	$593.82M	2.86	-$55.76M	-$2.76	N/A

Azenta has a net margin of -20.63% compared to Evotec's net margin of -26.20%. Azenta's return on equity of 1.18% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Azenta	-20.63%	1.18%	0.97%

In the previous week, Evotec and Evotec both had 5 articles in the media. Azenta's average media sentiment score of 0.36 beat Evotec's score of 0.04 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Azenta	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evotec currently has a consensus price target of $3.00, suggesting a potential upside of 87.50%. Azenta has a consensus price target of $41.20, suggesting a potential upside of 6.32%. Given Evotec's higher possible upside, research analysts clearly believe Evotec is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Evotec has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Azenta has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

5.8% of Evotec shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Azenta beats Evotec on 10 of the 13 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$585.32M	$10.57B	$7.14B	$13.18B
Dividend Yield	N/A	1.45%	2.53%	16.78%
P/E Ratio	N/A	74.99	275.68	26.04
Price / Sales	0.79	459.98	663.82	108.79
Price / Cash	N/A	26.96	77.60	51.75
Price / Book	0.62	6.85	10.93	6.31
Net Income	-$117.12M	$57.48B	$3.51B	$362.16M
7 Day Performance	2.56%	2.53%	-2.00%	-1.66%
1 Month Performance	-15.79%	8.43%	-6.15%	-4.50%
1 Year Performance	-60.10%	32.93%	7.44%	2.06%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	3.0829 of 5 stars	$1.60 -2.7%	$3.00 +87.5%	-58.8%	$585.32M	$717.28M	N/A	4,553
FTRE Fortrea	2.8145 of 5 stars	$20.30 +1.4%	$22.00 +8.4%	+108.3%	$1.93B	$2.72B	N/A	14,300	News Coverage Analyst Upgrade
MRVI Maravai LifeSciences	0.7346 of 5 stars	$7.30 +1.7%	$6.83 -6.3%	+166.0%	$1.89B	$185.74M	N/A	415
BLFS BioLife Solutions	2.4389 of 5 stars	$37.85 +1.8%	$31.38 -17.1%	+44.0%	$1.85B	$106.69M	32.63	155
PSNL Personalis	1.592 of 5 stars	$16.22 -0.1%	$14.54 -10.4%	+140.5%	$1.70B	$69.65M	N/A	260	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors